Gilead Sciences’ CEO John Milligan plans to step down at the end of the year, as Gilead continues to struggle with falling sales and profit.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.